General Info

Incorporated in 1999, Bioheart is a biotechnology company that focuses on the discovery, development and commercialization of regulatory-approval autologous cell therapies for the treatment of chronic and acute heart damage. It delivers devices that assist in monitoring, diagnosing and treating heart failures and cardiovascular diseases. The company offers products under the MyoCell brand, which is a clinical therapy that is designed to populate regions of scar tissue within a patient's heart with autologous muscle cells. It utilizes an endoventricular catheter for the treatment of heart damage. Bioheart works in partnership with Johnson & Johnson, which offers the NOGA cardiac navigation system along with MyoStar injection catheter for the delivery of MyoCell in MARVEL Trial. It is also involved in the development of cell-based therapies for the treatment of myocardial infarction. The company s product line includes MyoCath, MyoCell SDF-1, MyoCath II, BioPace and Allocell. It is a recipient of the South Florida Business Journal Technology Award.